1. Home
  2. Analysis
  3. Ceftazidime
  4. Gastrointestinal-perforation

Ceftazidime and Gastrointestinal perforation - a phase IV clinical study of FDA data

Summary:

Gastrointestinal perforation is reported as a side effect among people who take Ceftazidime (ceftazidime), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Vancomycin, and have Acute lymphocytic leukemia (all).

The phase IV clinical study analyzes which people have Gastrointestinal perforation when taking Ceftazidime. It is created by eHealthMe based on reports of 10,307 people who have side effects when taking Ceftazidime from the FDA, and is updated regularly.

What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,327 Ceftazidime users. Check the latest studies of Ceftazidime.

What is Gastrointestinal perforation?

Gastrointestinal perforation (hole in the digestive tract) is found to be associated with 928 drugs and 1,394 conditions by eHealthMe. Check the latest studies of Gastrointestinal perforation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

10,307 people reported to have side effects when taking Ceftazidime.
Among them, 13 people (0.13%) have Gastrointestinal perforation.

Could Ceftazidime cause Gastrointestinal perforation?

Among these 13 people:

How long have people been on Ceftazidime when they have Gastrointestinal perforation? *

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Gastrointestinal perforation when taking Ceftazidime? *

  • female: 33.33 %
  • male: 66.67 %

What is the age of people who have Gastrointestinal perforation when taking Ceftazidime? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 27.27 %
  • 20-29: 18.18 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 9.09 %
  • 60+: 45.45 %

What are other drugs people take besides Ceftazidime? *

  1. Vancomycin: 5 people, 38.46%
  2. Lasix: 2 people, 15.38%
  3. Blopress: 2 people, 15.38%
  4. Morphine: 2 people, 15.38%
  5. Cytotec: 2 people, 15.38%
  6. Cyclophosphamide: 2 people, 15.38%
  7. Maxipime: 2 people, 15.38%
  8. Buscopan: 2 people, 15.38%
  9. Dexamethasone: 2 people, 15.38%
  10. Ursodeoxycholic Acid: 2 people, 15.38%

What are other side effects people have besides Gastrointestinal perforation? *

  1. Ascites (accumulation of fluid in the abdominal cavity): 3 people, 23.08%
  2. Bone Marrow Failure: 3 people, 23.08%
  3. Haematochezia (passage of stools containing blood): 2 people, 15.38%
  4. Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall): 2 people, 15.38%
  5. Hypotension (abnormally low blood pressure): 2 people, 15.38%
  6. Hepatic Neoplasm (liver tumour): 2 people, 15.38%
  7. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 2 people, 15.38%
  8. Gastrointestinal Necrosis (destruction of gastrointestinal organ): 2 people, 15.38%
  9. Enteritis Infectious (infection with feline parvovirus (fpv), also known as feline panleucopenia virus): 2 people, 15.38%
  10. Constipation: 2 people, 15.38%

What are the existing conditions these people have? *

  1. Diarrhea: 3 people, 23.08%
  2. Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 3 people, 23.08%
  3. Squamous Cell Carcinoma (a cancer of a kind of epithelial cell): 2 people, 15.38%
  4. Neoplasm Progression (growth of tumour): 2 people, 15.38%
  5. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 15.38%
  6. Metastases To Central Nervous System (cancer spreads to central nervous system): 2 people, 15.38%
  7. Fever: 2 people, 15.38%
  8. Citrobacter Sepsis (infection by citrobacter (bacteria) in blood): 2 people, 15.38%
  9. Sepsis (a severe blood infection that can lead to organ failure and death): 1 person, 7.69%
  10. Peritonitis Bacterial (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs by bacterial): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftazidime and have Gastrointestinal perforation?

- Check whether Gastrointestinal perforation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ceftazidime:

Gastrointestinal perforation treatments and more:

How severe was Gastrointestinal perforation and when was it recovered:

Expand to all the drugs that have ingredients of ceftazidime:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ceftazidime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastrointestinal perforation:

Browse all the conditions that are associated with Gastrointestinal perforation:

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on ceftazidime (the active ingredients of Ceftazidime) and Ceftazidime (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.